



## **Praxis Precision Medicines to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022**

February 22, 2022

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- [Praxis Precision Medicines](#), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will provide a corporate update and report financial results for the fourth quarter and full year 2021 on Monday, February 28, 2022, before the U.S. financial markets open. Management will provide a video update highlighting recent business and pipeline progress in conjunction with a press release. Subsequently, management will host a separate Q&A session via a live conference call and webcast at 8:30 a.m. ET.

### **Conference Call and Webcast Details:**

US/Canada Toll-Free: 833-398-1037

International: 914-987-7735

Conference ID: 8993704

Webcast: <https://edge.media-server.com/mmc/p/dkhzv82n>

A replay of the webcast will be available approximately two hours following its conclusion and will be archived for 30 days following the event, accessible through the Events & Presentations page of the Investors + Media section of Praxis' website at <https://investors.praxismedicines.com/events-and-presentations>.

### **About Praxis**

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across psychiatric disorders, movement disorders, epilepsy and other CNS indications, with three clinical-stage product candidates. For more information, please visit [www.praxismedicines.com](http://www.praxismedicines.com) and follow us on [LinkedIn](#) and [Twitter](#).

Investor Contact: Alex Kane [Praxis Precision Medicines investors@praxismedicines.com](mailto:Praxis Precision Medicines investors@praxismedicines.com) 617-300-8481 Media Contact: Ian Stone Canale Communications [Ian.stone@canalecomm.com](mailto:Ian.stone@canalecomm.com) 619-849-5388